Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic virus with the potential to cause a
persistent infection, ultimately leading to cirrhosis and hepatocellular carcinoma. Over the …

Abstract Knowledge of the immunological events necessary to control hepatitis B virus
(HBV) infection has accelerated in recent years, but their translation towards therapeutic …

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest
rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection …

A sequence variation (I148M) in patatin‐like phospholipase domain‐containing protein 3
(PNPLA3) is strongly associated with fatty liver disease, but the underlying mechanism …

During the past 6 years, there have been substantial advances in our understanding of
human immunodeficiency virus 1 and other viruses, such as hepatitis B virus and hepatitis C …

Hepatitis B virus (HBV) is a major cause of chronic liver inflammation worldwide. Recent
knowledge of the virological and immunological events secondary to HBV infection has …

With the emergence of new viruses in the human population and the fast mutation rates of
existing viruses, new antiviral targets and compounds are needed. Most existing antiviral …

The employment of polymerase chain reaction (PCR) techniques for virus detection and
quantification offers the advantages of high sensitivity and reproducibility, combined with an …

The innate immune system has a role not only in protecting the host during the initial period
of virus infection, but also in shaping the nature of the adaptive immune response. In this …

Background & Aims: Entecavir is a novel and selective nucleoside analogue with potent
activity against hepatitis B virus (HBV). Methods: In a 24-week, double-blind, randomized …